Neurogene Inc. announced its financial results for the fourth quarter and full year 2024, highlighting significant progress in its NGN-401 Phase 1/2 trial for Rett syndrome. The company remains on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback